My Application Form Status

Check the status of your application form with Angel Broking.
Arq - The Hyper Intelligent Investment Engine By Angel Broking
Elgi Equipments drops after poor Q1 results
Jul 31,2017

The result was announced after market hours on Friday, 28 July 2017.

Meanwhile, the S&P BSE Sensex was up 86.19 points, or 0.27% at 32,396.07. The S&P BSE Mid-Cap index was up 26.82 points, or 0.17% at 15,356.38.

On the BSE, 6,939 shares were traded on the counter so far as against the average daily volumes of 5,604 shares in the past one quarter. The stock had hit a high of Rs 248.50 and a low of Rs 236.75 so far during the day. The stock had hit a record high of Rs 257.45 on 28 July 2017 and a 52-week low of Rs 159 on 4 August 2016.

The stock had outperformed the market over the past one month till 28 July 2017, advancing 5.36% compared with the Sensexs 4.79% rise. The scrip had also outperformed the market over the past one quarter advancing 22.52% as against the Sensexs 7.99% rise. The scrip had also outperformed the market over the past one year advancing 40.32% as against the Sensexs 14.54% rise.

The mid-cap company has equity capital of Rs 15.85 crore. Face value per share is Rs 1.

Elgi Equipments manufactures air compressors and automobile service station equipment.

Powered by Capital Market - Live News

NTPC rises after decent Q1 results
Jul 31,2017

The result was announced on Saturday, 29 July 2017.

Meanwhile, the S&P BSE Sensex was up 76.56 points, or 0.24% to 32,386.44.

On the BSE, 75,000 shares were traded in the counter so far, compared with average daily volumes of 6 lakh shares in the past one quarter. The stock had hit a high of Rs 167.90 and a low of Rs 164.40 so far during the day. The stock hit a 52-week high of Rs 177.80 on 27 January 2017. The stock hit a 52-week low of Rs 143.45 on 13 October 2016.

The stock had underperformed the market over the past one month till 28 July 2017, rising 3.57% compared with 4.71% rise in the Sensex. The scrip had also underperformed the market in past one quarter, falling 0.36% as against Sensexs 7.99% rise. The scrip had also underperformed the market in past one year, rising 3.38% as against Sensexs 15.18% rise.

The large-cap company has equity capital of Rs 8245.46 crore. Face value per share is Rs 10.

NTPC Group generated 71.606 billion units (BU) of power in Q1 June 2017 as against 71.5 BU generated in Q1 June 2016.

On standalone basis, NTPC generated 64.411 billion units. NTPC coal stations achieved plant load factor (PLF) of 79.05% in Q1 June 2017 as against National PLF of 62.49%, the statement added.

Further, during the quarter, hydro stations clocked plant availability factor (PAF) of over 103%, while coal stations and gas stations had availability factor of 88.96% and 88.19% respectively, it added. NTPC has installed capacity of 51,671 megawatts.

Meanwhile, NTPC announced on Saturday, 29 July 2017, that its board approved the issue of secured/ unsecured, redeemable, taxable/ tax-free, cumulative/ non-cumulative, non-convertible debentures (bonds/NCDs) upto Rs 15000 crore during the period commencing from the date of passing of special resolution in the ensuing annual general meeting till completion of one year thereof or the date of next annual general meeting in the financial year 2018-2019 whichever is earlier.

NTPC is Indias largest energy conglomerate with presence in the entire value chain of the power generation business.

Powered by Capital Market - Live News

L&T gains after Q1 result
Jul 31,2017

The result was announced after market hours on Friday, 28 July 2017.

Meanwhile, the S&P BSE Sensex was up 137.60 points, or 0.43% to 32,447.48.

On the BSE, 81,000 shares were traded in the counter so far, compared with average daily volumes of 5.97 lakh shares in the past one quarter. The stock had hit a high of Rs 1,202.80 and a low of Rs 1,182 so far during the day. The stock hit a 52-week high of Rs 1,223.28 on 30 May 2017. The stock hit a 52-week low of Rs 863.97 on 9 November 2016.

The stock had underperformed the market over the past one month till 28 July 2017, rising 2.13% compared with 4.71% rise in the Sensex. The scrip had also underperformed the market in past one quarter, falling 0.54% as against Sensexs 7.99% rise. The scrip had also underperformed the market in past one year, rising 11.59% as against Sensexs 15.18% rise.

The large-cap company has equity capital of Rs 280.06 crore. Face value per share is Rs 2.

On a consolidated basis, L&Ts net profit rose 50.60% to Rs 1028.30 crore on 9.59% rise in net sales to Rs 23810.86 crore in Q1 June 2017 over Q1 June 2016.

L&T won new orders worth Rs 26352 crore at consolidated level in Q1 June 2017 in a challenging business environment. International orders at Rs 7885 crore, constituted 30% of the total order inflow. Major orders during the quarter were secured by infrastructure segment. Consolidated order book of the group stood at Rs 262860 crore as on 30 June 2017, marginally higher by 2% on a year on year basis. International order book constituted 26% of the total order book.

L&T said that prospects of a good monsoon, rural wage growth, pay hike for state government employees, lower lending rates and a modest pick-up in external demand are expected to catalyse GDP growth. The company said its focus continues to be on selective order intake, working capital reduction, cost optimization through strengthening execution operational efficiencies and productivity enhancement through digitalization and other initiatives. The company is optimistic of its growth aspirations in the medium term as the economic outlook improves.

L&T is a major Indian multinational engaged in technology, engineering, construction, manufacturing and financial services.

Powered by Capital Market - Live News

Ballarpur Industries spurts after large bulk deal
Jul 28,2017

Meanwhile, the S&P BSE Sensex was down 57.27 points or 0.18% at 32,326.03. The S&P BSE Small-Cap index was up 55.75 points, or 0.35% at 16,071.22.

Bulk deal boosted volume on the scrip. On BSE, so far 39.93 lakh shares were traded on the counter as against average daily volume of 8.12 lakh shares in the past one quarter. The stock hit a high of Rs 17.60 and a low of Rs 16.30 so far during the day. The stock had hit a 52-week high of Rs 22.70 on 15 May 2017. The stock had hit a 52-week low of Rs 12.87 on 15 September 2016.

The stock had underperformed the market over the past one month till 27 July 2017, gaining 4.5% compared with 4.6% rise in the Sensex. The scrip, however, underperformed the market in past one quarter, falling 14.47% as against Sensexs 7.84% rise. The scrip had also underperformed the market in past one year, advancing 8.33% as against Sensexs 15.55% rise.

The small-cap company has an equity capital of Rs 131.10 crore. Face value per share is Rs 2.

Ballarpur Industries reported consolidated net loss of Rs 667.39 crore in Q4 March 2017, higher than net loss of Rs 182.11 crore in Q4 March 2016. Ballarpur Industries net sales fell 67.1% to Rs 357.51 crore in Q4 March 2017 over Q4 March 2015.

The Ballarpur Group is the largest manufacturer of writing and printing paper in India.

Powered by Capital Market - Live News

Reliance Capital leads gainers in A group
Jul 28,2017

Reliance Capital jumped 8.53% to Rs 715.35 at 14:55 IST. The stock topped the gainers in the BSEs A group. On the BSE, 16.44 lakh shares were traded on the counter so far as against the average daily volumes of 13.10 lakh shares in the past two weeks.

Firstsource Solutions surged 7.45% to Rs 35.35. The stock was the second biggest gainer in A group. On the BSE, 44.53 lakh shares were traded on the counter so far as against the average daily volumes of 3.63 lakh shares in the past two weeks.

JSW Energy gained 7.24% at Rs 71.80. The stock was the third biggest gainer in A group. On the BSE, 31.08 lakh shares were traded on the counter so far as against the average daily volumes of 10.18 lakh shares in the past two weeks.

Delta Corp advanced 5.4% to Rs 172.85. The stock was the fourth biggest gainer in A group. On the BSE, 9.63 lakh shares were traded on the counter so far as against the average daily volumes of 6.80 lakh shares in the past two weeks.

L&T Finance Holdings rose 5.33% to Rs 169.85. The stock was the fifth biggest gainer in A group. On the BSE, 16.50 lakh shares were traded on the counter so far as against the average daily volumes of 11.77 lakh shares in the past two weeks.

Powered by Capital Market - Live News

Reliance Capital jumps after reporting decent Q1 results
Jul 28,2017

The result was announced after market hours yesterday, 27 July 2017.

Meanwhile, the BSE Sensex was down 137.83 points, or 0.43%, to 32,231.50.

High volumes were witnessed on the counter. On the BSE, 14.74 lakh shares were traded in the counter so far, compared with average daily volume of 6.51 lakh shares in the past one quarter. The stock had hit a high of Rs 717.90 in intraday trade, which is also a 52-week high for the stock. The stock had hit a low of Rs 660.80 so far during the day. The stock had hit a 52-week low of Rs 407.50 on 27 December 2016.

The stock had underperformed the market over the past one month till 27 July 2017, gaining 0.11% compared with 4.6% rise in the Sensex. The scrip had also underperformed the market in past one quarter, falling 1.59% as against Sensexs 7.84% rise. The scrip, had, however, outperformed the market in past one year, gaining 52.94% as against Sensexs 15.55% rise.

The large-cap company has equity capital of Rs 252.66 crore. Face value per share is Rs 10.

Reliance Capital said that listing of Reliance Nippon Life Asset Management and Reliance General Insurance will be completed in FY 2018 subject to necessary regulatory approvals.

Reliance Capital, a part of the Reliance Group, is one of Indias leading private sector financial services companies.

Powered by Capital Market - Live News

Blue Dart descends after weak Q1 result
Jul 28,2017

The result was announced after market hours yesterday, 27 July 2017.

Meanwhile, the S&P BSE Sensex was down 143.75 points or 0.44% at 32,239.55

On BSE, so far 778 shares were traded in the counter as against average daily volume of 1,369 shares in the past one quarter. The stock hit a high of Rs 4,350 and a low of Rs 4,256.65 so far during the day. The stock had hit a 52-week high of Rs 6,088 on 28 July 2016. The stock had hit a 52-week low of Rs 4,160 on 16 July 2017.

The large-cap company has equity capital of Rs 23.73 crore. Face value per share is Rs 10.

Blue Dart Express accesses the largest and most comprehensive express and logistics network worldwide, covering over 220 countries and territories and offers an entire spectrum of distribution services including air express, freight forwarding, supply chain solutions and customs clearance.

Powered by Capital Market - Live News

Biocon skids after posting subdued Q1 results
Jul 28,2017

The result was announced after market hours yesterday, 27 July 2017.

Meanwhile, the S&P BSE Sensex was down 146.74 points or 0.45% at 32,236.56.

High volumes were witnessed on the counter. On the BSE, 4 lakh shares were traded on the counter so far as against the average daily volumes of 3.2 lakh shares in the past one quarter. The stock had hit a high of Rs 389.70 and a low of Rs 371.70 so far during the day. The stock had hit a record high of Rs 424.15 on 19 July 2017. The stock had hit a 52-week low of Rs 255.66 on 12 August 2016.

The stock had outperformed the market over the past one month till 27 July 2017, gaining 23.54% compared with 4.6% rise in the Sensex. The scrip, had, however, underperformed the market in past one quarter, rising 6.94% as against Sensexs 7.84% rise. The scrip, had, however, outperformed the market in past one year, gaining 48.3% as against Sensexs 15.55% rise.

The large-cap company has equity capital of Rs 300 crore. Face value per share is Rs 5.

Biocons revenue fell in Q1 June 2017 due to the combined impact of a stronger rupee, GST and the one‐time positive impact in Q1 June 2016 on account of the transition to IndAS.

Commenting on the quarterly performance and highlights, Chairperson and Managing Director Kiran Mazumdar‐Shaw stated that Biologics business had a strong quarter led by insulins sales. Financial performance was muted largely due to a combination of factors: weakening of dollar; GST impact; and inclusion of operational and fixed costs of Malaysia. Additionally, the yearly comparison was impacted by the one‐time adjustment in Q1 June 2016 related to IndAS migration.

The outlook for FY 2018 remains cautious as much depends on regulatory approvals and tender outcomes for companys biosimilars in key emerging markets. However, the company will endeavour to maintain healthy core operating margins, going forward, she added.

Biocon is Indias largest and fully-integrated, innovation-led biopharmaceutical company.

Powered by Capital Market - Live News

India Cements tanks after weak Q1 numbers
Jul 28,2017

The result was announced during market hours today, 28 July 2017.

Meanwhile, the S&P BSE Sensex was down 161.97 points, or 0.51% at 32,218.33. The S&P BSE Mid-Cap index was up 56.59 points, or 0.37% at 15,312.25.

High volumes were witnessed on the counter. On the BSE, 15.98 lakh shares were traded on the counter so far as against the average daily volumes of 5.94 lakh shares in the past one quarter. The stock had hit a high of Rs 218 and a low of Rs 199.20 so far during the day. The stock had hit a 52-week high of Rs 226 on 16 May 2017 and a 52-week low of Rs 104.65 on 21 November 2016.

The stock had underperformed the market over the past one month till 27 July 2017, advancing 14.28% compared with the Sensexs 4.6% rise. The scrip had also outperformed the market over the past one quarter gaining 1.98% as against the Sensexs 7.84% rise. The scrip had also outperformed the market over the past one year advancing 86.41% as against the Sensexs 15.55% rise.

The mid-cap company has equity capital of Rs 308.15 crore. Face value per share is Rs 10.

India Cements is one of the largest producers of cement in South India.

Powered by Capital Market - Live News

Glenmark Pharma gets healthier after posting robust Q1 results
Jul 28,2017

The result was announced after market hours yesterday, 27 July 2017.

Meanwhile, the BSE Sensex was down 178.25 points, or 0.55%, to 32,205.05.

High volumes were witnessed on the counter. On the BSE, 3.45 lakh shares were traded in the counter so far, compared with average daily volumes of 1.56 lakh shares in the past one quarter. The stock had hit a high of Rs 748 and a low of Rs 719 so far during the day. The stock had hit a 52-week high of Rs 993 on 1 November 2016. The stock had hit a 52-week low of Rs 600 on 29 May 2017.

The stock has gained 5.09% in four sessions to its ruling price from a close of Rs 688.90 on 24 July 2017.

The stock had outperformed the market over the past one month till 27 July 2017, gaining 13.68% compared with 4.6% rise in the Sensex. The scrip, had, however, underperformed the market in past one quarter, falling 18.98% as against Sensexs 7.84% rise. The scrip had also underperformed the market in past one year, dropping 15.86% as against Sensexs 15.55% rise.

The large-cap company has equity capital of Rs 28.22 crore. Face value per share is Re 1.

Glenmark Pharmaceuticals consolidated EBITDA (earnings before interest, taxes, depreciation and amortization) grew by 30.27% at Rs 592.73 crore in Q1 June 2017 over Q1 June 2016.

Glenn Saldanha, Chairman & MD, Glenmark Pharmaceuticals said that despite challenges in India and US markets, the performance of these businesses have been good. In India, the company continues to be one of the fastest growing company in the pharma market. In the US, after a steady stream of product approvals in the first quarter, the base business has rebounded well.

He added further that during Q1 June 2017, for GSP 301, the company received confirmation that the data from phase 3 trial is sufficient to support a new drug application (NDA) filing. This is an important milestone as GSP 301 will be the companys first NDA to be filed in the US.

Glenmark Pharmaceuticals is a research-driven, global, integrated pharmaceutical organization headquartered at Mumbai, India. The company is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). It has several molecules in various stages of clinical development and is primarily focused in the areas of oncology, dermatology and respiratory.

Powered by Capital Market - Live News

Volumes jump at Mahindra CIE Automotive counter
Jul 28,2017

Mahindra CIE Automotive clocked volume of 9.92 lakh shares by 12:30 IST on BSE, a 35.1-times surge over two-week average daily volume of 28,000 shares. The stock rose 2.33% at Rs 254.70.

HSIL notched up volume of 2.82 lakh shares, a 25.04-fold surge over two-week average daily volume of 11,000 shares. The stock advanced 1.67% at Rs 376.50.

Deccan Gold Mines saw volume of 26.3 lakh shares, a 14.78-fold surge over two-week average daily volume of 1.78 lakh shares. The stock was locked at 20% upper circuit at Rs 52.40.

GMR Infrastructure clocked volume of 2.81 crore shares, a 6.31-fold surge over two-week average daily volume of 44.64 lakh shares. The stock declined 1.55% at Rs 19.05.

Glenmark Pharmaceuticals saw volume of 3.28 lakh shares, a 4.88-fold rise over two-week average daily volume of 67,000 shares. The stock gained 1.02% at Rs 723.05 after consolidated net profit surged 47.01% to Rs 333.38 crore on 16.28% rise in total income to Rs 2378.29 crore in Q1 June 2017 over Q1 June 2016. The result was announced after market hours yesterday, 27 July 2017.

Powered by Capital Market - Live News

Escorts surges after reporting good Q1 earnings
Jul 28,2017

The result was announced during market hours today, 28 July 2017.

Meanwhile, the S&P BSE Sensex was down 159.78 points, or 0.49% at 32,223.52. The S&P BSE Mid-Cap index was up 73.83 points, or 0.48% at 15,329.49.

On the BSE, 3.53 lakh shares were traded on the counter so far as against the average daily volumes of 2.66 lakh shares in the past one quarter. The stock had hit a high of Rs 679.40 and a low of Rs 627.10 so far during the day. The stock had hit a record high of Rs 767.70 on 6 June 2017 and a 52-week low of Rs 247.20 on 27 July 2016.

The stock had underperformed the market over the past one month till 27 July 2017, declining 1.25% compared with the Sensexs 4.6% rise. The scrip had, however, outperformed the market over the past one quarter advancing 17.57% as against the Sensexs 7.84% rise. The scrip had also outperformed the market over the past one year advancing 153.69% as against the Sensexs 15.55% rise.

The mid-cap company has equity capital of Rs 122.58 crore. Face value per share is Rs 10.

Speaking on the results, Chairman Rajan Nanda said, Governments renewed focus on farm mechanisation and smart city infrastructure has provided positive momentum to the industry, resulting in to an upward trend in market demand. The company continues investing in technology, efficient distribution and product mix for enhanced agility, dynamism and customer responsiveness.

Escorts is one of Indias leading engineering conglomerates. The company has diversified business in to three different segments: escorts agri machinery, escorts construction equipment and railway equipment division.

Powered by Capital Market - Live News

ICICI Bank drops after poor Q1 result
Jul 28,2017

The result was announced after market hours yesterday, 27 July 2017.

Meanwhile, the S&P BSE Sensex was down 154.69 points, or 0.48%, to 32,228.61.

On the BSE, 4.86 lakh shares were traded in the counter so far, compared with average daily volume of 16.01 lakh shares in the past one quarter. The stock had hit a high of Rs 304 and a low of Rs 298.05 so far during the day. The stock had hit a 52-week low of Rs 215.41 on 4 August 2016. The stock had hit a 52-week high of Rs 314.50 on 27 August 2017.

The stock had outperformed the market over the past one month till 27 July 2017, gaining 5.43% compared with 4.6% rise in the Sensex. The scrip had also outperformed the market in past one quarter, rising 21.28% as against Sensexs 7.84% rise. The scrip had also outperformed the market in past one year, advancing 24.13% as against Sensexs 15.55% rise.

The large-cap private sector bank has equity capital of Rs 1282.63 crore. Face value per share is Rs 2.

ICICI Banks gross non-performing assets (NPAs) stood at Rs 43147.64 crore as on 30 June 2017 as against Rs 42551.54 crore as on 31 March 2017 and Rs 27562.93 crore as on 30 June 2016.

The ratio of gross NPAs to gross advances stood at 7.99% as on 30 June 2017 as against 7.89% as on 31 March 2017 and 5.28% as on 30 June 2016. The ratio of net NPAs to net advances stood at 4.86% as on 30 June 2017 as against 4.89% as on 31 March 2017 and 3.01% as on 30 June 2016.

The banks Net Interest Income (NII) grew by 8% to Rs 5590 crore in Q1 June 2017 over Q1 June 2016.

ICICI Bank is one of the leading private sector banks in India. The bank had a network of 4,852 branches and 13,780 ATMs at 30 June 2017.

Powered by Capital Market - Live News

Dr Reddys extends slide after announcing weak Q1 results
Jul 28,2017

Meanwhile, the S&P BSE Sensex was down 160.21 points or 0.49% at 32,220.87.

Higher than usual volumes were witnessed on the counter. On the BSE, 87,960 shares were traded on the counter so far as against the average daily volumes of 33,530 shares in the past one quarter. The stock had hit a high of Rs 2,530 and a low of Rs 2,465 so far during the day. The stock had hit a 52-week high of Rs 3,394.95 on 28 October 2016 and a 52-week low of Rs 2,382.05 on 29 May 2017.

The stock had underperformed the market over the past one month till 27 July 2017, sliding 1.24% compared with 4.6% rise in the Sensex. The scrip had also underperformed the market in past one quarter, rising 1.09% as against Sensexs 7.84% rise. The scrip had also underperformed the market in past one year, falling 12.28% as against Sensexs 15.55% rise.

The large-cap company has equity capital of Rs 82.91 crore. Face value per share is Rs 5.

Dr Reddys Laboratories consolidated net profit declined 56.61% to Rs 66.60 crore on 2.5% rise in net sales to Rs 3315.90 crore in Q1 June 2017 over Q1 June 2016. The result was announced during market hours yesterday, 27 July 2017. The stock had dropped 3.29% to Rs 2,621.45 yesterday, 27 July 2017 post announcement of results.

Dr Reddys Laboratories consolidated earnings before interest, taxation, depreciation and amortization (EBITDA) declined 15.56% to Rs 336 crore in Q1 June 2017 over Q1 June 2016. EBITDA margin contracted to 10.1% in Q1 June 2017, from 12.3% in Q1 June 2016.

Meanwhile, Dr Reddys Laboratories and CHD Bioscience Inc., a privately-held biopharmaceutical company, announced a global licensing agreement for the clinical development and commercialization of Dr Reddys phase III clinical trial candidate, DFA-02. The announcement was made after market hours yesterday, 27 July 2017.

It is intended to be used for the prevention of surgical site infections, following non-emergency, elective colorectal surgery. Phase II studies for DFA-02 have been successfully completed, and the product will be transitioning to pivotal Phase III registration studies.

Under the terms of the agreement, Dr Reddys would receive equity in CHD valued at $30 million upon an initial public offer (IPO) of CHD or a minimum of $30 million in cash within 18 months of execution of the agreement. Dr Reddys will also receive additional milestone payments of $40 million upon US drug regulators approval. In addition, CHD will pay Dr Reddys double-digit royalties on sales and commercial milestones.

Dr Reddys Laboratories is an integrated global pharmaceutical company.

Powered by Capital Market - Live News

Idea Cellular skids after reverse turnaround in Q1
Jul 28,2017

The result was announced after market hours yesterday, 27 July 2017.

Meanwhile, the S&P Sensex was down 155.54 points or 0.48% at 32,227.76.

On the BSE, 10.11 lakh shares were traded on the counter so far as against the average daily volumes of 16.76 lakh shares in the past one quarter. The stock had hit a high of Rs 92.45 and a low of Rs 87.30 so far during the day.

The stock had hit a 52-week high of Rs 123.75 on 20 March 2017 and a 52-week low of Rs 66 on 9 November 2016.

The stock has dropped 6.08% in three sessions to its current price from a close of Rs 97.80 on 25 July 2017.

The stock had outperformed the market over the past one month till 27 July 2017, gaining 14.17% compared with 4.6% rise in the Sensex. The scrip had also outperformed the market in past one quarter, rising 8.55% as against Sensexs 7.84% rise. The scrip had, however, underperformed the market in past one year, falling 12.88% as against Sensexs 15.55% rise.

The large-cap company has equity capital of Rs 3606.41 crore. Face value per share is Rs 10.

Idea Cellulars total income fell 14.34% to Rs 8181.70 crore in Q1 June 2017 over Q1 June 2016. EBITDA (earnings before interest, taxes, depreciation and amortization) margin fell to 25.6% in Q1 June 2017 from 29.1% in Q1 June 2016.

The financial stress in the mobile sector remains at its peak, post the introduction of aggressive unlimited bundled plans by new entrant forcing other operators to follow. Resultantly, all Telecom Service Providers are reporting steep decline in revenues, profitability and cash flows and all but one Indian wireless operator quarterly results are likely to show significant financial losses, company added.

Idea Cellular is one of the leading telecom operators in India.

Powered by Capital Market - Live News